Navigation Links
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
Date:3/13/2008

SCHAUMBURG, Ill., March 13 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections. Sagent's Cefazolin for injection will be available in 1g single dose vials and 10g pharmacy bulk package vials. According to IMS data, sales of Cefazolin in the United States in 2006 were approximately $69 million.

The introduction of Cefazolin for injection marks the second product launch in three months from Sagent's pipeline of more than 200 products. The launch of Cefazolin for injection follows Sagent's December 2007 introduction of the first full-line of latex-free, multi-source prefilled, ready-to-use, 6 mg and 12 mg, adenosine syringes in the market. Sagent will begin marketing and shipping Cefazolin immediately.

"The launch of Cefazolin, the first product to emerge from our extensive anti-infective pipeline, marks further progress toward Sagent's ultimate goal of becoming a leader in the injectables marketplace," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "This product provides our customers another sourcing option for this important antibiotic and, as with all Sagent products, offers enhanced labeling intended to optimize product safety and increase efficiency in the hospital."

About Cefazolin

Cefazolin for injection, USP, is the generic equivalent of GlaxoSmithKline's ANCEF(R), an antibiotic used to treat bacterial infections. Cefazolin for injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by various strains of streptococci. Prophylactic Cefazolin for injection, USP, preoperative, intraopertative and postoperative administration can be effective in reducing the incidence of certain surgical infections. The most common adverse effects may include mild nausea, diarrhea, oral candidiasis and pain or tenderness at the injection site. Less common adverse effects include vomiting, and rarely, pseudomembranous colitis.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... addition of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently ... as Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, ...
(Date:5/3/2016)... THE WOODLANDS, Texas , May 3, 2016 /PRNewswire/ ... board certified plastic surgeon in The Woodlands, ... technology that destroys 24 percent of treated fat cells ... men and woman. Close to 90 percent of Americans ... effective treatment options. Nonsurgical fat reduction procedures are a ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... clients in mind, the fresh look and added functionality give the agricultural world ... have seen a dynamic shift in agriculture – from precision farming via satellites ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/9/2016)... , March 9, 2016 This BCC Research ... states of the RNA Sequencing (RNA Seq) market for ... as instruments, tools and reagents, data analysis, and services. ... segments of the RNA-Sequencing market such as RNA-Sequencing tools ... the main factors affecting each segment and forecast their ...
Breaking Biology News(10 mins):